• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page
Dude you are a bit fast to call it a success:

1 - it's costing shitloads of money
2 - everybody complains about the quality (but nobody cares)
3 - the worst is ahead for sure :)

but keep posting you success fantasy on yammer you POS
 








Dude you are a bit fast to call it a success:

1 - it's costing shitloads of money
2 - everybody complains about the quality (but nobody cares)
3 - the worst is ahead for sure :)

but keep posting you success fantasy on yammer you POS

Yammer brings me closer to our leaders. They unboss me.

The money is well spent. With stride we have the latest and best tools. We have the smartest people. We are a team. More power to HD
 












Dude you are a bit fast to call it a success:

1 - it's costing shitloads of money
2 - everybody complains about the quality (but nobody cares)
3 - the worst is ahead for sure :)

but keep posting you success fantasy on yammer you POS

I hear and read nothing in Yammer about the quality. It is a success. We are a digital and data company now. Success
 
































He's mainly an amateur who has made our monitoring a big joke, our data management a big joke, our biometric a big joke and keep touting everywhere that's a fu**ing success. The worst is that the idiot will probably leave when the shit hit the fan with a fat check and we will need 10 years to rebuild after the indian show ends.